LAG3 Antikörper (full length)

Produktnummer ABIN7878542

Dieser Maus Monoklonal Antikörper detektiert spezifisch LAG3 in ELISA. Es zeigt Reaktivität gegenüber Proben von Human.

Kurzübersicht für LAG3 Antikörper (full length) (ABIN7878542)

Target: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser LAG3 Antikörper ist unkonjugiert

Applikation: ELISA

Güteklasse: Carrier-free

Klon: LAG3-3261

Produktdetails anti-LAG3 Antikörper

Bindungsspezifität: full length

Verwendungszweck: LAG3 Antibody / Lymphocyte activation gene 3 / CD223 (azide and preservative free)

Aufreinigung: Protein G affinity chromatography

Immunogen: A recombinant full-length human LAG3 protein was used as the immunogen for this LAG3 antibody.

Isotyp: IgG2a, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the LAG3 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store the LAG3 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Details zu LAG3

Target: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Andere Bezeichnung: LAG3

Hintergrund: LAG-3 (also called CD223) is a high affinity MHC class II ligand present on the surface of CD4+CD8+ T cells and NK cell, with shared homology in structure to CD4 Molecules. It has a glutamic acid-proline (EP) repetitive sequence found in other functionally distinct mammalian, parasitic, and bacterial proteins that may influence a conserved biological function. LAG-3+CD4+CD8+ T cells can associate with the T cell receptor (TCR) and downregulate TCR signaling in vitro. LAG-3 inhibits CD4-dependent T cell function via its cytoplasmic domain. LAG-3 Lys-468 within a conserved 'KIEELE' motif is essential for interaction with downstream signaling molecules. Furthermore, as a checkpoint inhibitor target, it may be superior to CTLA-4 and PD-1 since both antibodies only activate effector T-cells, whereas an antagonist LAG-3 antibody can both activate T effector cells (by downregulating the LAG-3 inhibiting signal into pre-activated LAG-3+ cells) and inhibit induced (i.e. antigen-specific) Treg suppressive activity.

UniProt: P18627

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints